Investigating new treatments for triple-negative breast cancer
BLRD Research Career Scientist Award Application
This study is looking at ways to slow down the growth of triple-negative breast cancer by focusing on a protein called CCN5/WISP-2, with the hope of finding new treatment options that could help patients like you have better outcomes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kansas City VA Medical Center NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project ID | NIH-10948930 on NIH RePORTER |
What this research studies
This research focuses on triple-negative breast cancer (TNBC), a type of breast cancer that lacks hormone receptors and is known for its aggressive nature and limited treatment options. The study aims to identify molecules that can inhibit tumor progression in TNBC, particularly a protein called CCN5/WISP-2, which has shown promise in modulating cancer growth. By exploring targeted therapeutic regimens, the research seeks to improve outcomes for patients suffering from this challenging form of breast cancer. Patients may benefit from potential new treatment strategies that could enhance their response to therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer who have limited treatment options.
Not a fit: Patients with other types of breast cancer or those who have already exhausted all treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that improve survival rates and quality of life for patients with triple-negative breast cancer.
How similar studies have performed: While initial trials with checkpoint inhibitors have shown some promise, the specific approach of targeting CCN5/WISP-2 in TNBC is relatively novel and has not been extensively tested.
Where this research is happening
Kansas City, United States
- Kansas City VA Medical Center — Kansas City, United States (Active)
Researchers
- Principal investigator: Banerjee, Sushanta K. — Kansas City VA Medical Center
- Study coordinator: Banerjee, Sushanta K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.